Stoke Therapeutics, Inc. (STOK) Q3 FY2026 earnings

Reported results

• Revenue recognized for the three months ended September 30, 2026, was $11.3 million, compared to $10.6 million for the same period in 2025.
• Net loss for the three months ended September 30, 2026, was $73.6 million (including non-cash stock-based compensation expense of $11.0 million), or $1.08 per share, compared to a net loss of $38.3 million, or $0.65 per share, for the same period in 2025.
• Research and development expenses for the three months ended September 30, 2026, were $59.8 million, compared to $37.7 million for the same period in 2025.
• Sales, general and administrative expenses for the three months ended September 30, 2026, were $28.7 million, compared to $16.0 million for the same period in 2025.
• Cash, cash equivalents and marketable securities totaled $358.8 million as of September 30, 2026.

Guidance

• Cash, cash equivalents and marketable securities of $358.8 million as of September 30, 2026, are expected to fund operations into early 2028.

Price and volatility reaction

The stock moved -0.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -50.6 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.